{
    "clinical_study": {
        "@rank": "25212", 
        "arm_group": [
            {
                "arm_group_label": "Exparel", 
                "arm_group_type": "Active Comparator", 
                "description": "266mg/20mL Exparel (to be diluted with 10 mL sterile saline to make 30 mL)"
            }, 
            {
                "arm_group_label": "Bupivacaine HCl with epinephrine", 
                "arm_group_type": "Active Comparator", 
                "description": "75mg/30mL 0.25% Bupivacaine HCl with epinephrine"
            }, 
            {
                "arm_group_label": "Normal Saline", 
                "arm_group_type": "Placebo Comparator", 
                "description": "30mL Normal Saline"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the quality and duration of pain relief after a\n      hemorrhoidectomy, provided by locally administered liposomal bupivacaine versus bupivacaine\n      hcl or control with saline. It is hypothesized that liposomal bupivacaine will provide more\n      effective postoperative pain relief than both bupivacaine hcl and the control."
        }, 
        "brief_title": "Efficacy of Rectal Infiltration of Exparel for Analgesic Benefit Following Hemorrhoidectomy", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hemorrhoid", 
        "condition_browse": {
            "mesh_term": "Hemorrhoids"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  patients undergoing hemorrhoidectomy for grade 3 or 4 hemorrhoids who are\n             English-speaking patients, 21-65 yr of age, ASA physical status I-III, BMI<30\n\n        Exclusion Criteria:\n\n          -  contraindications to administration of local anesthesia (e.g., local anesthetic\n             allergy), difficult airway (Mallampati>2), psychiatric or cognitive disorders,\n             pregnancy , and history of substance abuse or chronic opioid use"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02104414", 
            "org_study_id": "13-0062"
        }, 
        "intervention": [
            {
                "arm_group_label": "Exparel", 
                "description": "266 mg/20mL Exparel (to be diluted with 10 mL sterile saline to make 30 mL)", 
                "intervention_name": "Exparel", 
                "intervention_type": "Drug", 
                "other_name": "Liposomal Bupivacaine"
            }, 
            {
                "arm_group_label": "Bupivacaine HCl with epinephrine", 
                "description": "75mg/30mL 0.25% Bupivacaine HCl with epinephrine", 
                "intervention_name": "Bupivacaine HCl with Epinephrine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Normal Saline", 
                "description": "30mL Normal Saline", 
                "intervention_name": "Normal Saline", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Epinephrine", 
                "Epinephryl borate", 
                "Bupivacaine", 
                "Analgesics"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Liposomal Bupivacaine", 
            "Exparel"
        ], 
        "lastchanged_date": "April 1, 2014", 
        "location": {
            "contact": {
                "email": "alishariatmd@gmail.com", 
                "last_name": "Ali Shariat, MD", 
                "phone": "914-409-5023"
            }, 
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York"
                }, 
                "name": "St.Luke's-Roosevelt Hospital Center"
            }, 
            "investigator": [
                {
                    "last_name": "Ali Shariat, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Admir Hadzic, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Nipa Gandhi, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Comparison of Rectal Infiltration of Exparel vs. 0.25% Bupivacaine With Epinephrine vs. Placebo for Analgesic Benefit Following Hemorrhoidectomy", 
        "overall_contact": {
            "email": "alishariatmd@gmail.com", 
            "last_name": "Ali Shariat, MD", 
            "phone": "914-409-5023"
        }, 
        "overall_official": {
            "affiliation": "St. Luke's-Roosevelt Hospital Center", 
            "last_name": "Ali Shariat, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary objective is to evaluate analgesia following local infiltration of 30 mL Exparel or the same volume of 0.25% bupivacaine HCl with epinephrine or normal saline. The intensity of pain will be measured using a numerical rating scale (NRS-11) in which 0 represents no pain, and 10 represents extreme pain.", 
            "measure": "Post operative pain control", 
            "safety_issue": "No", 
            "time_frame": "The first 96 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02104414"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Postoperative opioid consumption", 
                "safety_issue": "No", 
                "time_frame": "Hourly from PACU arrival to discharge and Q4H from 10:00-22:00 postoperatively for 4 days"
            }, 
            {
                "measure": "Postoperative nausea and vomiting", 
                "safety_issue": "Yes", 
                "time_frame": "Hourly from PACU arrival to discharge and Q4H from 10:00-22:00 postoperatively for 4 days"
            }, 
            {
                "measure": "Frequency of and pain during postoperative bowel movements", 
                "safety_issue": "Yes", 
                "time_frame": "Hourly from PACU arrival to discharge and Q4H from 10:00-22:00 postoperatively for 4 days"
            }, 
            {
                "measure": "Incidence of urinary retention", 
                "safety_issue": "Yes", 
                "time_frame": "Hourly from PACU arrival to discharge and Q4H from 10:00-22:00 postoperatively for 4 days"
            }
        ], 
        "source": "St. Luke's-Roosevelt Hospital Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "St. Luke's-Roosevelt Hospital Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}